Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Estimation of the Optimal Treatment Duration and Cumulative Dose of BP-C1 in Breast Cancer Patients With Distant Metastases: a Dose-response Study (IC)

NCT03789019 is registered in ClinicalTrials.gov with Meabco A/S as lead sponsor.

NCT NCT03789019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03789019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Estimation of the Optimal Treatment Duration and Cumulative Dose of BP-C1 in Breast Cancer Patients With Distant Metastases: a Dose-response Study (IC)
Lead sponsor
Meabco A/S
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2013
Completion date
July 29, 2016
Enrollment
29 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, stage iv breast cancer